Company Overview of Sequella, Inc.
Sequella, Inc., a clinical stage biopharmaceutical company, develops and commercializes treatment products for diagnosis and treatment of infectious diseases. The company’s products include TB Patch, a point-of-care diagnostic used to diagnose active tuberculosis (TB) infection; SQ109, a molecule anti-TB drug; drug compliance monitor, a medical device that records when medication is taken; SQ609, an antibiotic compound for vitro and in vivo anti-TB activities; and SQ641, a natural product for the treatment of TB or bacterial pneumonia. Sequella, Inc. was founded in 1997 and is based in Rockville, Maryland.
9610 Medical Center Drive
Rockville, MD 20850
Founded in 1997
Key Executives for Sequella, Inc.
Sequella, Inc. Key Developments
Similar Private Companies By Industry
|AuraZyme Pharmaceuticals, Inc.||United States|
|Microbes BioSciences, Inc.||United States|
|Alopexx Pharmaceuticals, LLC||United States|
|Stratatech Corporation||United States|
|American Gene Technologies International Inc.||United States|
Recent Private Companies Transactions
August 28, 2013
To contact Sequella, Inc., please visit www.sequella.com. Company data is provided by Capital IQ. Please use this form to report any data issues.